Advertisement

Topics

Sosei Subsidiary Heptares and Daiichi Sankyo to Discover and Develop Novel, Small-Molecules for the Treatment of Pain

03:05 EDT 13 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Sosei Group Corporation (“Sosei”; TSE Mothers Index:4565) reported that its subsidiaries, Heptares Therapeutics (“Heptares”) has announced that it have entered into a drug discovery and licensing agreement with Daiichi S...

Other Sources for this Article

Contact for Sosei
Harumi BANSE, +81-(0)3-5210-3399
Investor Relations
hbanse@sosei.com

NEXT ARTICLE

More From BioPortfolio on "Sosei Subsidiary Heptares and Daiichi Sankyo to Discover and Develop Novel, Small-Molecules for the Treatment of Pain"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...